ALK+ Blog/News
-
Clinical Trials for ALK-positive Cancers – Are They for Me?
Should I enroll in a clinical trial for ALK-positive cancer? The decision to enroll in a clinical trial requires a real understanding of what is being studied and how you […]
-
Protect Funding for Lung Cancer and ALK-positive Cancer Research
ATLANTA, February 20, 2025 – The ALK Positive organization stands with patients, families, healthcare providers, researchers, and the broader medical community in our mission to increase survival for those at risk, diagnosed, and living with ALK-positive cancer. We are deeply concerned with the devastating impact that severely and suddenly reducing the budget of the National…
-
RAISE YOUR VOICE AS A CANCER PATIENT: Advocacy Letter Template
Dear Senator (or Congress woman/man) XXXXX, As one of your constituents from XXXXXX, I wanted to let you know that I am deeply concerned about the current administration’s funding cuts to NIH. For the past XXX years I have been living with stage 4 lung cancer – ALK positive – a subtype that has FDA…
-
ALK Positive Announces Formation of Distinguished Scientific Advisory Board
ALK Positive, in collaboration with 23andMe Holding Co., a leading genetic health and biopharmaceutical company, and 20 lung cancer advocacy organizations, today announces a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to…
-
Dana Querido
We interviewed patient and ALK Positive volunteer Dana Querido about her journey with ALK+ lung cancer and her active involvement with the ALKtALK Healing Arts, Death Cafe, and more.
-
Introducing ALK Positive UK: Founded by Debra Montague
Debra Montague was diagnosed in October 2016 and joined the world-wide ALK Positive Facebook support group. She came to realise that there was a need for a UK group to address issues that are specific to UK patients, e.g. the National Health Service, the Driving Licence Regulator and the Drugs Approval Regulator. In July 2018,…
-
Jeff Sturm
During the Thanksgiving holiday, over a liter of pleural fluid was withdrawn via needle from my right chest space. I had just finished my third cycle of Carboplatin, Pemetrexed, and Lorlatinib after almost ten years of TKIs alone. The fluid first became evident on a PET scan and was classified as moderate effusion. I didn’t…
-
My Family’s Favorite Oven-Baked Brisket: By Chef and fellow ALKie, Juli Posner
I’m sure there are a lot of people in many parts of the country that wouldn’t dream of making a brisket in the oven. But growing up in New York on Long Island, we never owned a smoker. I think once you try this virtually fuss-free, oven-baked method, you will be sold by how delicious…
-
Amanda Bialack-Stewart
Amanda has been actively involved in ALK Positive, Inc. through creating and leading the Young ALKies Group. We interviewed her in Los Angeles, California about having been diagnosed right after giving birth to twins at the age of 36, how she manages to balance family, work, fun, and self-care as a patient.
-
Amivantamab With Tyrosine Kinase Inhibitors (TKIs) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Who is this trial for: This trial is for patients with one of three forms of non-small cell lung cancer (NSCLC) – ALK, ROS1, or RET – who are progressing on their current TKI under certain conditions, and are willing to try an experimental drug combination in order to extend the life of their current…
-
Rich Gopen
Rich Gopen is an ALK patient and one of our match donors for Lung Cancer Awareness Month (LCAM). We interviewed Rich about his journey with ALK+ lung cancer, what motivates him, and his hopes for the future.
-
Phase II Clinical Trial NCT05384626 by Nuvalent, Inc. A Study of NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…